amlodipine has been researched along with Insulin Resistance in 43 studies
Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.
amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.
Insulin Resistance: Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Compared with amlodipine group, fasting blood insulin levels and insulin resistance index (HOMA-IR) were significantly decreased in losartan group, and in addition, the circulating levels of 8-OHdG and NT were significantly decreased in losartan group, while the serum SOD activity was enhanced." | 9.20 | Losartan reduces insulin resistance by inhibiting oxidative stress and enhancing insulin signaling transduction. ( Fu, SK; Gu, HF; Hu, C; Jin, HM; Liu, XL; Pan, LH; Pan, Y; Qiao, QY; Zhou, DC, 2015) |
| " The aim of this study was to evaluate the effects of a fixed-dose olmesartan/amlodipine combination on blood pressure control, lipid profile, insulin sensitivity, and inflammation compared to singles monotherapies." | 9.19 | Results from a 12 months, randomized, clinical trial comparing an olmesartan/amlodipine single pill combination to olmesartan and amlodipine monotherapies on blood pressure and inflammation. ( Carbone, A; Cicero, AF; D'Angelo, A; Derosa, G; Fogari, E; Maffioli, P; Querci, F, 2014) |
| " This study evaluated the effects of an olmesartan/amlodipine single pill combination compared to olmesartan or amlodipine monotherapies on BP, lipid profile, insulin resistance, and insulin sensitivity parameters." | 9.17 | Olmesartan/amlodipine combination versus olmesartan or amlodipine monotherapies on blood pressure and insulin resistance in a sample of hypertensive patients. ( Carbone, A; Cicero, AF; D'Angelo, A; Derosa, G; Fogari, E; Maffioli, P; Querci, F, 2013) |
| "In patients with hypertension and metabolic syndrome, manidipine, both alone and in combination with the ACE inhibitor lisinopril, is significantly superior to amlodipine for improving insulin sensitivity as well as several metabolic, inflammatory and prothrombotic markers." | 9.15 | Effects of manidipine and its combination with an ACE inhibitor on insulin sensitivity and metabolic, inflammatory and prothrombotic markers in hypertensive patients with metabolic syndrome: the MARCADOR study. ( Comi-Diaz, C; Macias-Batista, A; Martinez-Martin, FJ; Pedrianes-Martin, P; Rodriguez-Rosas, H; Soriano-Perera, P, 2011) |
| "We studied the effects of treatment with olmesartan/amlodipine and olmesartan/hydrochlorothiazide on inflammatory and metabolic parameters (including new-onset diabetes as a secondary endpoint) in non-diabetic hypertensive patients with metabolic syndrome (MetS)." | 9.15 | Olmesartan/amlodipine vs olmesartan/hydrochlorothiazide in hypertensive patients with metabolic syndrome: the OLAS study. ( Comi-Diaz, C; Martinez-Martin, FJ; Pedrianes-Martin, P; Peiro-Martinez, I; Rodriguez-Rosas, H; Soriano-Perera, P, 2011) |
| "To evaluate the effects of manidipine versus amlodipine on blood pressure, albuminuria, insulin sensitivity, adiponectin, TNF-alpha and C-reactive protein in nondiabetic subjects with metabolic syndrome (ATP-III definition), including impaired fasting glucose (>5." | 9.14 | Manidipine in hypertensive patients with metabolic syndrome: the MARIMBA study. ( Martínez Martín, FJ, 2009) |
| " Serum insulin, glucose, C-reactive protein (CRP), lipids, uric acid, YKL-40 and blood pressure were measured and insulin sensitivity was calculated (HOMA) at the beginning and end of each study phase." | 9.14 | Effect of moxonidine and amlodipine on serum YKL-40, plasma lipids and insulin sensitivity in insulin-resistant hypertensive patients-a randomized, crossover trial. ( Majer, J; Masajtis-Zagajewska, A; Nowicki, M, 2010) |
| " Since treatment with angiotensin II receptor blockers retards the development of diabetes, the effects of losartan on serum adiponectin levels were examined with regard to insulin sensitivity in pre-diabetic patients." | 9.13 | Losartan elevates the serum high-molecular weight-adiponectin isoform and concurrently improves insulin sensitivity in patients with impaired glucose metabolism. ( Higuchi, C; Naito, T; Nishimura, H; Otsuka, K; Sanaka, T; Tanihata, Y, 2008) |
| "This study aimed to clarify the impact of telmisartan on fat distribution and insulin sensitivity in the metabolic syndrome." | 9.12 | Effects of telmisartan on fat distribution in individuals with the metabolic syndrome. ( Shimabukuro, M; Shimabukuro, T; Tanaka, H, 2007) |
| " Furthermore, C-peptide concentrations, the insulin sensitivity index, and the insulin-to-glucose ratio were significantly increased after 3 months of therapy with losartan as compared to amlodipine (P<0." | 9.12 | Angiotensin type-1 receptor blockade with losartan increases insulin sensitivity and improves glucose homeostasis in subjects with type 2 diabetes and nephropathy. ( Jin, HM; Pan, Y, 2007) |
| "The objective of this study was to assess the effect of amlodipine-atorvastatin combination on plasma interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha) and insulin sensitivity in normocholesterolemic obese hypertensive patients." | 9.12 | Effects of amlodipine-atorvastatin combination on inflammation markers and insulin sensitivity in normocholesterolemic obese hypertensive patients. ( Ciccarelli, L; Corradi, L; Derosa, G; Fogari, E; Fogari, R; Lazzari, P; Preti, P; Zoppi, A, 2006) |
| "The aim of this study was to evaluate the effect of the amlodipine-atorvastatin combination on plasma tissue plasminogen activator (t-PA) and plasminogen activator inhibitor type 1 (PAI-1) activity in hypercholesterolemic, hypertensive patients with insulin resistance." | 9.11 | Effect of amlodipine-atorvastatin combination on fibrinolysis in hypertensive hypercholesterolemic patients with insulin resistance. ( Derosa, G; Fogari, E; Fogari, R; Lazzari, P; Mugellini, A; Rinaldi, A; Zoppi, A, 2004) |
| "To demonstrate that calcium channel blockers can improve insulin resistance clinically, we investigated the effects of the calcium channel blockers, amlodipine, manidipine and cilnidipine on serum levels of steroid hormones and insulin." | 9.11 | Effects of the long-acting calcium channel blockers, amlodipine, manidipine and cilnidipine on steroid hormones and insulin resistance in hypertensive obese patients. ( Miyachi, Y; Ueshiba, H, 2004) |
| "This study compares the effects of a calcium channel blocker (amlodipine) and an angiotensin converting enzyme inhibitor (enalapril) on in vivo insulin sensitivity in patients with essential hypertension." | 9.09 | A double blind comparison of the effects of amlodipine and enalapril on insulin sensitivity in hypertensive patients. ( Arauz-Pacheco, C; Breen, L; Lender, D; Mora-Mora, P; Ramirez, LC; Raskin, P, 1999) |
| "Amlodipine and perindopril have beneficial effect on improving insulin sensitivity in EH patients with decreased insulin sensitivity." | 9.08 | [The effect of amlodipine, nifedipine and perindopril on insulin sensitivity and blood lipid of patients with essential hypertension]. ( Chen, D; Lin, J; Wu, K, 1998) |
| "Compared with amlodipine, fimasartan increased late-phase glucose-stimulated insulin secretion in patients with type 2 diabetes and hypertension." | 7.88 | Fimasartan increases glucose-stimulated insulin secretion in patients with type 2 diabetes and hypertension compared with amlodipine. ( Ahn, CH; Cho, YM; Jung, HS; Kim, S; Kwak, SH; Lee, SO; Lim, MH; Mari, A; Park, KS; Roh, E; Yang, YS, 2018) |
| "SHR/NDmcr-cp (SHRcp), a rat model of human metabolic syndrome, were divided into four groups, and were administered (i) vehicle, (ii) candesartan (an ARB) 0." | 7.78 | Amlodipine enhances amelioration of vascular insulin resistance, oxidative stress, and metabolic disorders by candesartan in metabolic syndrome rats. ( Dong, YF; Kataoka, K; Kim-Mitsuyama, S; Koibuchi, N; Nakamura, T; Ogawa, H; Sueta, D; Toyama, K; Yamamoto, E; Yasuda, O, 2012) |
| "To clarify whether the long-acting calcium-channel blocker amlodipine restores insulin insensitivity in essential hypertension, insulin sensitivity tests were performed at the physiological steady-state insulin level (45 to 55 microU/mL) before and after amlodipine (2." | 7.69 | Improvement of insulin sensitivity for glucose metabolism with the long-acting Ca-channel blocker amlodipine in essential hypertensive subjects. ( Asakura, Y; Harano, Y; Hirose, J; Ikebuchi, M; Kageyama, A; Omae, T; Suzuki, M; Yokota, T, 1995) |
| "To evaluate the effects of long-term treatment antihypertensive with the dihydropyridine calcium antagonist amlodipine on insulin sensitivity, plasma insulin, and lipoprotein metabolism in obese hypertensive patients." | 7.68 | Lack of effect of long-term amlodipine on insulin sensitivity and plasma insulin in obese patients with essential hypertension. ( Böhlen, L; de Courten, M; Ferrari, P; Heynen, G; Riesen, W; Schneider, M; Shaw, S; Weidmann, P, 1993) |
| "Eighty subjects with type 2 diabetic nephropathy were randomly divided into two groups: losarten group (n = 41) and amlodipine group (n = 39)." | 6.74 | Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan. ( Guo, LL; Jin, HM; Pan, Y, 2009) |
| "Insulin resistance (IR) in chronic renal failure (CRF) is well-known." | 6.70 | Doxazosin, but not amlodipine decreases insulin resistance in patients with chronic renal failure: a prospective, randomized-controlled study. ( Akkaya, V; Celik, AV; Gürol, AO; Hursit, M; Karsidag, K; Kayacan, SM; Yazici, H; Yildiz, A, 2002) |
| "There is lacking evidence that telmisartan can improve insulin resistance in patients on high-intensity statins." | 5.51 | Effects of high-intensity statin combined with telmisartan versus amlodipine on glucose metabolism in hypertensive atherosclerotic cardiovascular disease patients with impaired fasting glucose: A randomized multicenter trial. ( Kang, TS; Kim, BK; Kim, JY; Lee, CJ; Lee, SH; Park, S; Sung, JH, 2022) |
| " Compared with amlodipine group, fasting blood insulin levels and insulin resistance index (HOMA-IR) were significantly decreased in losartan group, and in addition, the circulating levels of 8-OHdG and NT were significantly decreased in losartan group, while the serum SOD activity was enhanced." | 5.20 | Losartan reduces insulin resistance by inhibiting oxidative stress and enhancing insulin signaling transduction. ( Fu, SK; Gu, HF; Hu, C; Jin, HM; Liu, XL; Pan, LH; Pan, Y; Qiao, QY; Zhou, DC, 2015) |
| " The aim of this study was to evaluate the effects of a fixed-dose olmesartan/amlodipine combination on blood pressure control, lipid profile, insulin sensitivity, and inflammation compared to singles monotherapies." | 5.19 | Results from a 12 months, randomized, clinical trial comparing an olmesartan/amlodipine single pill combination to olmesartan and amlodipine monotherapies on blood pressure and inflammation. ( Carbone, A; Cicero, AF; D'Angelo, A; Derosa, G; Fogari, E; Maffioli, P; Querci, F, 2014) |
| "To evaluate the safety and efficacy of a fixed olmesartan/amlodipine (Olme/Amlo) combination in improving blood pressure control, lipid profile, insulin sensitivity and some inflammatory and insulin resistance markers." | 5.17 | Evaluation of safety and efficacy of a fixed olmesartan/amlodipine combination therapy compared to single monotherapies. ( Carbone, A; Cicero, AF; D'Angelo, A; Derosa, G; Fogari, E; Maffioli, P; Querci, F, 2013) |
| " This study evaluated the effects of an olmesartan/amlodipine single pill combination compared to olmesartan or amlodipine monotherapies on BP, lipid profile, insulin resistance, and insulin sensitivity parameters." | 5.17 | Olmesartan/amlodipine combination versus olmesartan or amlodipine monotherapies on blood pressure and insulin resistance in a sample of hypertensive patients. ( Carbone, A; Cicero, AF; D'Angelo, A; Derosa, G; Fogari, E; Maffioli, P; Querci, F, 2013) |
| " The aim of this study was to evaluate the effects of losartan or amlodipine alone or combined with simvastatin on hepatic steatosis degree, and on insulin sensitivity in normocholesterolemic, hypertensive patients with nonalcoholic hepatic steatosis." | 5.16 | Effects of losartan and amlodipine alone or combined with simvastatin in hypertensive patients with nonalcoholic hepatic steatosis. ( Derosa, G; Fogari, R; Lazzari, P; Maffioli, P; Mugellini, A; Zoppi, A, 2012) |
| "We studied the effects of treatment with olmesartan/amlodipine and olmesartan/hydrochlorothiazide on inflammatory and metabolic parameters (including new-onset diabetes as a secondary endpoint) in non-diabetic hypertensive patients with metabolic syndrome (MetS)." | 5.15 | Olmesartan/amlodipine vs olmesartan/hydrochlorothiazide in hypertensive patients with metabolic syndrome: the OLAS study. ( Comi-Diaz, C; Martinez-Martin, FJ; Pedrianes-Martin, P; Peiro-Martinez, I; Rodriguez-Rosas, H; Soriano-Perera, P, 2011) |
| "In patients with hypertension and metabolic syndrome, manidipine, both alone and in combination with the ACE inhibitor lisinopril, is significantly superior to amlodipine for improving insulin sensitivity as well as several metabolic, inflammatory and prothrombotic markers." | 5.15 | Effects of manidipine and its combination with an ACE inhibitor on insulin sensitivity and metabolic, inflammatory and prothrombotic markers in hypertensive patients with metabolic syndrome: the MARCADOR study. ( Comi-Diaz, C; Macias-Batista, A; Martinez-Martin, FJ; Pedrianes-Martin, P; Rodriguez-Rosas, H; Soriano-Perera, P, 2011) |
| " Serum insulin, glucose, C-reactive protein (CRP), lipids, uric acid, YKL-40 and blood pressure were measured and insulin sensitivity was calculated (HOMA) at the beginning and end of each study phase." | 5.14 | Effect of moxonidine and amlodipine on serum YKL-40, plasma lipids and insulin sensitivity in insulin-resistant hypertensive patients-a randomized, crossover trial. ( Majer, J; Masajtis-Zagajewska, A; Nowicki, M, 2010) |
| "To evaluate the effects of manidipine versus amlodipine on blood pressure, albuminuria, insulin sensitivity, adiponectin, TNF-alpha and C-reactive protein in nondiabetic subjects with metabolic syndrome (ATP-III definition), including impaired fasting glucose (>5." | 5.14 | Manidipine in hypertensive patients with metabolic syndrome: the MARIMBA study. ( Martínez Martín, FJ, 2009) |
| " Since treatment with angiotensin II receptor blockers retards the development of diabetes, the effects of losartan on serum adiponectin levels were examined with regard to insulin sensitivity in pre-diabetic patients." | 5.13 | Losartan elevates the serum high-molecular weight-adiponectin isoform and concurrently improves insulin sensitivity in patients with impaired glucose metabolism. ( Higuchi, C; Naito, T; Nishimura, H; Otsuka, K; Sanaka, T; Tanihata, Y, 2008) |
| "The objective of this study was to assess the effect of amlodipine-atorvastatin combination on plasma interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha) and insulin sensitivity in normocholesterolemic obese hypertensive patients." | 5.12 | Effects of amlodipine-atorvastatin combination on inflammation markers and insulin sensitivity in normocholesterolemic obese hypertensive patients. ( Ciccarelli, L; Corradi, L; Derosa, G; Fogari, E; Fogari, R; Lazzari, P; Preti, P; Zoppi, A, 2006) |
| " Furthermore, C-peptide concentrations, the insulin sensitivity index, and the insulin-to-glucose ratio were significantly increased after 3 months of therapy with losartan as compared to amlodipine (P<0." | 5.12 | Angiotensin type-1 receptor blockade with losartan increases insulin sensitivity and improves glucose homeostasis in subjects with type 2 diabetes and nephropathy. ( Jin, HM; Pan, Y, 2007) |
| "This study aimed to clarify the impact of telmisartan on fat distribution and insulin sensitivity in the metabolic syndrome." | 5.12 | Effects of telmisartan on fat distribution in individuals with the metabolic syndrome. ( Shimabukuro, M; Shimabukuro, T; Tanaka, H, 2007) |
| "We evaluated whether the changes in the insulin sensitivity observed in hypertensive patients following treatment with an angiotensin II receptor blocker (candesartan) or calcium-channel antagonist (amlodipine) might be related to improvement of the endothelial function (END) and/or plasma level of high-sensitive C-reactive protein (CRP) following such treatment." | 5.12 | Discrepancy between improvement of insulin sensitivity and that of arterial endothelial function in patients receiving antihypertensive medication. ( Koji, Y; Motobe, K; Shiina, K; Tomiyama, H; Yamada, J; Yamashina, A; Yambe, M; Yoshida, M, 2007) |
| "To demonstrate that calcium channel blockers can improve insulin resistance clinically, we investigated the effects of the calcium channel blockers, amlodipine, manidipine and cilnidipine on serum levels of steroid hormones and insulin." | 5.11 | Effects of the long-acting calcium channel blockers, amlodipine, manidipine and cilnidipine on steroid hormones and insulin resistance in hypertensive obese patients. ( Miyachi, Y; Ueshiba, H, 2004) |
| "The aim of this study was to evaluate the effect of the amlodipine-atorvastatin combination on plasma tissue plasminogen activator (t-PA) and plasminogen activator inhibitor type 1 (PAI-1) activity in hypercholesterolemic, hypertensive patients with insulin resistance." | 5.11 | Effect of amlodipine-atorvastatin combination on fibrinolysis in hypertensive hypercholesterolemic patients with insulin resistance. ( Derosa, G; Fogari, E; Fogari, R; Lazzari, P; Mugellini, A; Rinaldi, A; Zoppi, A, 2004) |
| "This study compares the effects of a calcium channel blocker (amlodipine) and an angiotensin converting enzyme inhibitor (enalapril) on in vivo insulin sensitivity in patients with essential hypertension." | 5.09 | A double blind comparison of the effects of amlodipine and enalapril on insulin sensitivity in hypertensive patients. ( Arauz-Pacheco, C; Breen, L; Lender, D; Mora-Mora, P; Ramirez, LC; Raskin, P, 1999) |
| "Amlodipine and perindopril have beneficial effect on improving insulin sensitivity in EH patients with decreased insulin sensitivity." | 5.08 | [The effect of amlodipine, nifedipine and perindopril on insulin sensitivity and blood lipid of patients with essential hypertension]. ( Chen, D; Lin, J; Wu, K, 1998) |
| "Compared with amlodipine, fimasartan increased late-phase glucose-stimulated insulin secretion in patients with type 2 diabetes and hypertension." | 3.88 | Fimasartan increases glucose-stimulated insulin secretion in patients with type 2 diabetes and hypertension compared with amlodipine. ( Ahn, CH; Cho, YM; Jung, HS; Kim, S; Kwak, SH; Lee, SO; Lim, MH; Mari, A; Park, KS; Roh, E; Yang, YS, 2018) |
| "Telmisartan exerted anti-obesity effects and restored leptin sensitivity, given as a treatment to rats with obesity." | 3.80 | Chronic blockade of angiotensin AT₁ receptors improves cardinal symptoms of metabolic syndrome in diet-induced obesity in rats. ( Barkhausen, J; Hübel, N; Mildner, M; Müller-Fielitz, H; Raasch, W; Vogt, FM, 2014) |
| " Metformin treatment improved the insulin sensitivity, and normalized the in vitro bladder hypercontractility and cystometric dysfunction in obese mice." | 3.78 | Role of PKC and CaV1.2 in detrusor overactivity in a model of obesity associated with insulin resistance in mice. ( Anhê, GF; Antunes, E; Calixto, MC; De Nucci, G; Grant, AD; Leiria, LO; Lintomen, L; Mónica, FZ; Sollon, C; Zanesco, A, 2012) |
| "SHR/NDmcr-cp (SHRcp), a rat model of human metabolic syndrome, were divided into four groups, and were administered (i) vehicle, (ii) candesartan (an ARB) 0." | 3.78 | Amlodipine enhances amelioration of vascular insulin resistance, oxidative stress, and metabolic disorders by candesartan in metabolic syndrome rats. ( Dong, YF; Kataoka, K; Kim-Mitsuyama, S; Koibuchi, N; Nakamura, T; Ogawa, H; Sueta, D; Toyama, K; Yamamoto, E; Yasuda, O, 2012) |
| "To clarify whether the long-acting calcium-channel blocker amlodipine restores insulin insensitivity in essential hypertension, insulin sensitivity tests were performed at the physiological steady-state insulin level (45 to 55 microU/mL) before and after amlodipine (2." | 3.69 | Improvement of insulin sensitivity for glucose metabolism with the long-acting Ca-channel blocker amlodipine in essential hypertensive subjects. ( Asakura, Y; Harano, Y; Hirose, J; Ikebuchi, M; Kageyama, A; Omae, T; Suzuki, M; Yokota, T, 1995) |
| "To evaluate the effects of long-term treatment antihypertensive with the dihydropyridine calcium antagonist amlodipine on insulin sensitivity, plasma insulin, and lipoprotein metabolism in obese hypertensive patients." | 3.68 | Lack of effect of long-term amlodipine on insulin sensitivity and plasma insulin in obese patients with essential hypertension. ( Böhlen, L; de Courten, M; Ferrari, P; Heynen, G; Riesen, W; Schneider, M; Shaw, S; Weidmann, P, 1993) |
| "Eighty subjects with type 2 diabetic nephropathy were randomly divided into two groups: losarten group (n = 41) and amlodipine group (n = 39)." | 2.74 | Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan. ( Guo, LL; Jin, HM; Pan, Y, 2009) |
| "Insulin resistance was measured by homeostasis assessment index (HOMA)." | 2.73 | Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome. ( Acikel, C; Caglar, K; Celik, T; Eyileten, T; Oguz, Y; Sonmez, A; Vural, A; Yavuz, I; Yenicesu, M; Yilmaz, MI, 2007) |
| "Treatment with indapamide was followed by a significant decrease of plasma adiponectin concentration." | 2.73 | Indapamide decreases plasma adiponectin concentration in patients with essential hypertension. ( Adamczak, M; Chudek, J; Piecha, G; Wiecek, A, 2007) |
| "Hypertension in type 2 diabetes represents a strong risk factor for cardiovascular events." | 2.72 | The effects of telmisartan and amlodipine on metabolic parameters and blood pressure in type 2 diabetic, hypertensive patients. ( Hassan, H; Negro, R, 2006) |
| "Insulin resistance (IR) in chronic renal failure (CRF) is well-known." | 2.70 | Doxazosin, but not amlodipine decreases insulin resistance in patients with chronic renal failure: a prospective, randomized-controlled study. ( Akkaya, V; Celik, AV; Gürol, AO; Hursit, M; Karsidag, K; Kayacan, SM; Yazici, H; Yildiz, A, 2002) |
| "Amlodipine treatment 1) lowered fasting serum insulin (from 273 +/- 19 to 200 +/- 17 pmol/L; P < 0." | 2.67 | The calcium channel blocker amlodipine raises serum dehydroepiandrosterone sulfate and androstenedione, but lowers serum cortisol, in insulin-resistant obese and hypertensive men. ( Beer, NA; Beer, RM; Jakubowicz, DJ; Nestler, JE, 1993) |
| "Atorvastatin treatment of fructose-fed rats increased vascular BH4 content, which was associated with an increase in endothelial NO synthase activity as well as a reduction in endothelial O2(-) production." | 1.40 | Effects of atorvastatin, amlodipine, and their combination on vascular dysfunction in insulin-resistant rats. ( Geddawy, A; Imamura, T; Iwasaki, H; Masada, M; Okamura, T; Shimosato, T; Shinozaki, K; Shintaku, H; Tawa, M; Yoshida, Y, 2014) |
| "Rosiglitazone-treated rats had restored systolic blood pressure (BP) and normalized plasma insulin level during oral glucose tolerance tests, whereas amlodipine-treated rats restored only systolic BP." | 1.35 | Myocardial heat shock protein 60 expression in insulin-resistant and diabetic rats. ( Chen, HS; Juan, CC; Lin, HD; Wu, TE, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (16.28) | 18.2507 |
| 2000's | 18 (41.86) | 29.6817 |
| 2010's | 17 (39.53) | 24.3611 |
| 2020's | 1 (2.33) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, CJ | 1 |
| Sung, JH | 1 |
| Kang, TS | 1 |
| Park, S | 1 |
| Lee, SH | 1 |
| Kim, JY | 1 |
| Kim, BK | 1 |
| Yang, YS | 1 |
| Lim, MH | 1 |
| Lee, SO | 1 |
| Roh, E | 1 |
| Ahn, CH | 1 |
| Kwak, SH | 1 |
| Cho, YM | 1 |
| Kim, S | 1 |
| Mari, A | 1 |
| Park, KS | 1 |
| Jung, HS | 1 |
| Derosa, G | 7 |
| Cicero, AF | 4 |
| Carbone, A | 4 |
| Querci, F | 4 |
| Fogari, E | 6 |
| D'Angelo, A | 4 |
| Maffioli, P | 5 |
| Tepliakov, AE | 1 |
| Pushnikova, EIu | 1 |
| Kaliuzhin, VV | 1 |
| Bespalova, ID | 1 |
| Kaliuzhina, EV | 1 |
| Kaliuzhina, MI | 1 |
| Okamura, T | 1 |
| Tawa, M | 1 |
| Geddawy, A | 1 |
| Shimosato, T | 1 |
| Iwasaki, H | 1 |
| Shintaku, H | 1 |
| Yoshida, Y | 1 |
| Masada, M | 1 |
| Shinozaki, K | 2 |
| Imamura, T | 1 |
| Müller-Fielitz, H | 1 |
| Hübel, N | 1 |
| Mildner, M | 1 |
| Vogt, FM | 1 |
| Barkhausen, J | 1 |
| Raasch, W | 1 |
| Pan, Y | 3 |
| Qiao, QY | 1 |
| Pan, LH | 1 |
| Zhou, DC | 1 |
| Hu, C | 1 |
| Gu, HF | 1 |
| Fu, SK | 1 |
| Liu, XL | 1 |
| Jin, HM | 3 |
| Furuhashi, M | 1 |
| Mita, T | 1 |
| Moniwa, N | 1 |
| Hoshina, K | 1 |
| Ishimura, S | 1 |
| Fuseya, T | 1 |
| Watanabe, Y | 1 |
| Yoshida, H | 1 |
| Shimamoto, K | 1 |
| Miura, T | 1 |
| Aksnes, TA | 2 |
| Flaa, A | 1 |
| Sevre, K | 1 |
| Mundal, HH | 1 |
| Rostrup, M | 1 |
| Kjeldsen, SE | 2 |
| Chen, HS | 1 |
| Wu, TE | 1 |
| Juan, CC | 1 |
| Lin, HD | 1 |
| Nishimura, H | 1 |
| Sanaka, T | 1 |
| Tanihata, Y | 1 |
| Naito, T | 1 |
| Higuchi, C | 1 |
| Otsuka, K | 1 |
| Guo, LL | 1 |
| Martínez Martín, FJ | 1 |
| Masajtis-Zagajewska, A | 1 |
| Majer, J | 1 |
| Nowicki, M | 1 |
| Martinez-Martin, FJ | 2 |
| Rodriguez-Rosas, H | 2 |
| Peiro-Martinez, I | 1 |
| Soriano-Perera, P | 2 |
| Pedrianes-Martin, P | 2 |
| Comi-Diaz, C | 2 |
| Macias-Batista, A | 1 |
| Fogari, R | 3 |
| Mugellini, A | 2 |
| Zoppi, A | 3 |
| Lazzari, P | 3 |
| Sueta, D | 1 |
| Nakamura, T | 1 |
| Dong, YF | 1 |
| Kataoka, K | 1 |
| Koibuchi, N | 1 |
| Yamamoto, E | 1 |
| Toyama, K | 1 |
| Yasuda, O | 1 |
| Ogawa, H | 1 |
| Kim-Mitsuyama, S | 1 |
| Maeda, A | 1 |
| Tamura, K | 1 |
| Kanaoka, T | 1 |
| Ohsawa, M | 1 |
| Haku, S | 1 |
| Azushima, K | 1 |
| Dejima, T | 1 |
| Wakui, H | 1 |
| Yanagi, M | 1 |
| Okano, Y | 1 |
| Fujikawa, T | 1 |
| Toya, Y | 1 |
| Mizushima, S | 1 |
| Tochikubo, O | 1 |
| Umemura, S | 1 |
| Leiria, LO | 1 |
| Sollon, C | 1 |
| Calixto, MC | 1 |
| Lintomen, L | 1 |
| Mónica, FZ | 1 |
| Anhê, GF | 1 |
| De Nucci, G | 1 |
| Zanesco, A | 1 |
| Grant, AD | 1 |
| Antunes, E | 1 |
| Yildiz, A | 1 |
| Hursit, M | 1 |
| Celik, AV | 1 |
| Kayacan, SM | 1 |
| Yazici, H | 1 |
| Akkaya, V | 1 |
| Gürol, AO | 1 |
| Karsidag, K | 1 |
| Ueshiba, H | 1 |
| Miyachi, Y | 1 |
| Rinaldi, A | 1 |
| Ersoy, C | 1 |
| Imamoğlu, S | 1 |
| Budak, F | 1 |
| Tuncel, E | 1 |
| Ertürk, E | 1 |
| Oral, B | 1 |
| Ikeda, T | 1 |
| Gomi, T | 1 |
| Shibuya, Y | 1 |
| Matsuo, K | 1 |
| Kosugi, T | 1 |
| Oku, N | 1 |
| Uetake, Y | 1 |
| Kinugasa, S | 1 |
| Furutera, R | 1 |
| Preti, P | 1 |
| Corradi, L | 1 |
| Ciccarelli, L | 1 |
| Reims, HM | 1 |
| Guptha, S | 1 |
| Moan, A | 1 |
| Os, I | 1 |
| Negro, R | 1 |
| Hassan, H | 1 |
| Shimabukuro, M | 1 |
| Tanaka, H | 1 |
| Shimabukuro, T | 1 |
| Tomiyama, H | 1 |
| Yambe, M | 1 |
| Yamada, J | 1 |
| Motobe, K | 1 |
| Koji, Y | 1 |
| Yoshida, M | 1 |
| Shiina, K | 1 |
| Yamashina, A | 1 |
| Yilmaz, MI | 1 |
| Sonmez, A | 1 |
| Caglar, K | 1 |
| Celik, T | 1 |
| Yenicesu, M | 1 |
| Eyileten, T | 1 |
| Acikel, C | 1 |
| Oguz, Y | 1 |
| Yavuz, I | 1 |
| Vural, A | 1 |
| Piecha, G | 1 |
| Adamczak, M | 1 |
| Chudek, J | 1 |
| Wiecek, A | 1 |
| Harano, Y | 2 |
| Kageyama, A | 1 |
| Hirose, J | 1 |
| Asakura, Y | 1 |
| Yokota, T | 1 |
| Ikebuchi, M | 1 |
| Suzuki, M | 2 |
| Omae, T | 1 |
| de Courten, M | 1 |
| Ferrari, P | 1 |
| Schneider, M | 1 |
| Böhlen, L | 1 |
| Shaw, S | 1 |
| Riesen, W | 1 |
| Heynen, G | 1 |
| Weidmann, P | 1 |
| Beer, NA | 1 |
| Jakubowicz, DJ | 1 |
| Beer, RM | 1 |
| Nestler, JE | 1 |
| Hara, Y | 1 |
| Ryomoto, K | 1 |
| Kanazawa, A | 1 |
| Nishioheda, Y | 1 |
| Tsushima, M | 1 |
| Srinivasan, PS | 1 |
| Hakim, ZS | 1 |
| Santani, DD | 1 |
| Goyal, RK | 1 |
| Lender, D | 1 |
| Arauz-Pacheco, C | 1 |
| Breen, L | 1 |
| Mora-Mora, P | 1 |
| Ramirez, LC | 1 |
| Raskin, P | 1 |
| Lin, J | 1 |
| Chen, D | 1 |
| Wu, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Adiponectin is Positively Associated With Insulin Resistance in Subjects With Type 2 Diabetic Nephropathy and Effects by Angiotensin Type 1 Receptor Blocker Losartan[NCT00774904] | 80 participants (Actual) | Interventional | 2007-04-30 | Completed | |||
| Glucose Optimisation With Angiotensin II Antagonist Losartan in Patients With Hypertension and Other Risk Factors for Metabolic Syndrome (GOAAL)[NCT00237588] | Phase 4 | 25 participants | Interventional | 2004-12-31 | Completed | ||
| Valsartan Versus Amlodipine Effect on Left Ventricular Multidirectional Deformation and Adipocytokines Level in Hypertensive Patients: Speckle Tracking Echocardiography[NCT03990480] | Phase 4 | 230 participants (Actual) | Interventional | 2018-12-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
30 trials available for amlodipine and Insulin Resistance
| Article | Year |
|---|---|
Effects of high-intensity statin combined with telmisartan versus amlodipine on glucose metabolism in hypertensive atherosclerotic cardiovascular disease patients with impaired fasting glucose: A randomized multicenter trial.
Topics: Amlodipine; Atherosclerosis; Cardiovascular Diseases; Fasting; Glucose; Heart Diseases; Humans; Hydr | 2022 |
Evaluation of safety and efficacy of a fixed olmesartan/amlodipine combination therapy compared to single monotherapies.
Topics: Adipokines; Amlodipine; Blood Glucose; Blood Pressure; Body Mass Index; Body Weight; Double-Blind Me | 2013 |
[The influence of amlodipine on transcapillary metabolism of oxygen during coronary heart disease with insulin resistance].
Topics: Amlodipine; Capillary Permeability; Coronary Circulation; Coronary Disease; Humans; Insulin Resistan | 2013 |
Results from a 12 months, randomized, clinical trial comparing an olmesartan/amlodipine single pill combination to olmesartan and amlodipine monotherapies on blood pressure and inflammation.
Topics: Amlodipine; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Mass Index; Body Weight; Do | 2014 |
Different aspects of sartan + calcium antagonist association compared to the single therapy on inflammation and metabolic parameters in hypertensive patients.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Body M | 2014 |
Losartan reduces insulin resistance by inhibiting oxidative stress and enhancing insulin signaling transduction.
Topics: 3T3-L1 Cells; Adipocytes; Aged; Amlodipine; Animals; Antihypertensive Agents; Diabetic Nephropathies | 2015 |
Effects on plasma noradrenaline may explain some of the improved insulin sensitivity seen by AT-1 receptor blockade.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Cross-Over Studies; Doubl | 2008 |
Losartan elevates the serum high-molecular weight-adiponectin isoform and concurrently improves insulin sensitivity in patients with impaired glucose metabolism.
Topics: Adiponectin; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Fe | 2008 |
Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan.
Topics: Adiponectin; Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Diabe | 2009 |
Manidipine in hypertensive patients with metabolic syndrome: the MARIMBA study.
Topics: Adiponectin; Adult; Aged; Aged, 80 and over; Albuminuria; Amlodipine; Antihypertensive Agents; Blood | 2009 |
Effect of moxonidine and amlodipine on serum YKL-40, plasma lipids and insulin sensitivity in insulin-resistant hypertensive patients-a randomized, crossover trial.
Topics: Adipokines; Adult; Amlodipine; Antihypertensive Agents; Biomarkers; Blood Pressure; Body Size; Chiti | 2010 |
Olmesartan/amlodipine vs olmesartan/hydrochlorothiazide in hypertensive patients with metabolic syndrome: the OLAS study.
Topics: Adiponectin; Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; C-Reactive Protein; C | 2011 |
Effects of manidipine and its combination with an ACE inhibitor on insulin sensitivity and metabolic, inflammatory and prothrombotic markers in hypertensive patients with metabolic syndrome: the MARCADOR study.
Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimid | 2011 |
Effects of losartan and amlodipine alone or combined with simvastatin in hypertensive patients with nonalcoholic hepatic steatosis.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; | 2012 |
Combination therapy of angiotensin II receptor blocker and calcium channel blocker exerts pleiotropic therapeutic effects in addition to blood pressure lowering: amlodipine and candesartan trial in Yokohama (ACTY).
Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Ben | 2012 |
Olmesartan/amlodipine combination versus olmesartan or amlodipine monotherapies on blood pressure and insulin resistance in a sample of hypertensive patients.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Body Mass Index; Body Weight; Double-Blind Meth | 2013 |
Doxazosin, but not amlodipine decreases insulin resistance in patients with chronic renal failure: a prospective, randomized-controlled study.
Topics: Adult; Amlodipine; Antihypertensive Agents; Doxazosin; Female; Homeostasis; Humans; Insulin Resistan | 2002 |
Effects of the long-acting calcium channel blockers, amlodipine, manidipine and cilnidipine on steroid hormones and insulin resistance in hypertensive obese patients.
Topics: Aged; Amlodipine; Analysis of Variance; Body Mass Index; Calcium Channel Blockers; Dehydroepiandrost | 2004 |
Effect of amlodipine-atorvastatin combination on fibrinolysis in hypertensive hypercholesterolemic patients with insulin resistance.
Topics: Adult; Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Drug Thera | 2004 |
Effects of amlodipine-atorvastatin combination on inflammation markers and insulin sensitivity in normocholesterolemic obese hypertensive patients.
Topics: Adult; Aged; Amlodipine; Atorvastatin; Biomarkers; Blood Glucose; Body Mass Index; Calcium Channel B | 2006 |
Improved insulin sensitivity with the angiotensin II-receptor blocker losartan in patients with hypertension and other cardiovascular risk factors.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biomarkers; Bloo | 2006 |
Angiotensin type-1 receptor blockade with losartan increases insulin sensitivity and improves glucose homeostasis in subjects with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Blood Glucose; C-Peptide; Calcium | 2007 |
The effects of telmisartan and amlodipine on metabolic parameters and blood pressure in type 2 diabetic, hypertensive patients.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Blood Pressure | 2006 |
Effects of telmisartan on fat distribution in individuals with the metabolic syndrome.
Topics: Adipose Tissue, White; Adult; Aged; Amlodipine; Analysis of Variance; Angiotensin II Type 1 Receptor | 2007 |
Discrepancy between improvement of insulin sensitivity and that of arterial endothelial function in patients receiving antihypertensive medication.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; | 2007 |
Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome.
Topics: Adiponectin; Adrenergic beta-Antagonists; Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers | 2007 |
Indapamide decreases plasma adiponectin concentration in patients with essential hypertension.
Topics: Adiponectin; Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; Enalapril; Female; Glomerul | 2007 |
The calcium channel blocker amlodipine raises serum dehydroepiandrosterone sulfate and androstenedione, but lowers serum cortisol, in insulin-resistant obese and hypertensive men.
Topics: Adult; Amlodipine; Androgens; Androstenedione; Calcium Channel Blockers; Dehydroepiandrosterone; Deh | 1993 |
A double blind comparison of the effects of amlodipine and enalapril on insulin sensitivity in hypertensive patients.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Glucose; Calciu | 1999 |
[The effect of amlodipine, nifedipine and perindopril on insulin sensitivity and blood lipid of patients with essential hypertension].
Topics: Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Female; Humans; Hypertension; Insulin | 1998 |
13 other studies available for amlodipine and Insulin Resistance
| Article | Year |
|---|---|
Fimasartan increases glucose-stimulated insulin secretion in patients with type 2 diabetes and hypertension compared with amlodipine.
Topics: Aged; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Cro | 2018 |
Effects of atorvastatin, amlodipine, and their combination on vascular dysfunction in insulin-resistant rats.
Topics: Amlodipine; Animals; Atorvastatin; Biopterins; Blood Pressure; Calcium Channel Blockers; Cardiovascu | 2014 |
Chronic blockade of angiotensin AT₁ receptors improves cardinal symptoms of metabolic syndrome in diet-induced obesity in rats.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Obesity Agents; Antihypertensive | 2014 |
Angiotensin II receptor blockers decrease serum concentration of fatty acid-binding protein 4 in patients with hypertension.
Topics: 3T3 Cells; Adrenergic beta-Agonists; Amlodipine; Angiotensin II Type 2 Receptor Blockers; Animals; A | 2015 |
Myocardial heat shock protein 60 expression in insulin-resistant and diabetic rats.
Topics: Amlodipine; Animals; Antihypertensive Agents; Chaperonin 60; Diabetes Mellitus, Experimental; Diseas | 2009 |
Amlodipine enhances amelioration of vascular insulin resistance, oxidative stress, and metabolic disorders by candesartan in metabolic syndrome rats.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Bl | 2012 |
Role of PKC and CaV1.2 in detrusor overactivity in a model of obesity associated with insulin resistance in mice.
Topics: Adiposity; Amlodipine; Animals; Body Weight; Calcium Channel Blockers; Calcium Channels, L-Type; Cal | 2012 |
Effect of amlodipine on insulin resistance & tumor necrosis factor-alpha levels in hypertensive obese type 2 diabetic patients.
Topics: Adolescent; Adult; Aged; Amlodipine; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Female; Ho | 2004 |
Morning rise in blood pressure is a predictor of left ventricular hypertrophy in treated hypertensive patients.
Topics: Activity Cycles; Aged; Amlodipine; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Calcium Ch | 2004 |
Improvement of insulin sensitivity for glucose metabolism with the long-acting Ca-channel blocker amlodipine in essential hypertensive subjects.
Topics: Amlodipine; Blood Glucose; Catecholamines; Female; Glucose Tolerance Test; Homeostasis; Humans; Hype | 1995 |
Lack of effect of long-term amlodipine on insulin sensitivity and plasma insulin in obese patients with essential hypertension.
Topics: Amlodipine; Blood Pressure; Female; Humans; Hypertension; Insulin; Insulin Resistance; Male; Middle | 1993 |
Clinical impact of insulin resistance syndrome in cardiovascular diseases and its therapeutic approach.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Blo | 1996 |
Effects of chronic treatment with amlodipine in streptozotocin-diabetic and spontaneously hypertensive rats.
Topics: Amlodipine; Animals; Blood Glucose; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Exp | 1997 |